1236060-10-8

Basic information

• Product Name: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide
• Synonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide
• CAS NO: 1236060-10-8
• Molecular Weight: 406.525
• Mol File: 1236060-10-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide(1236060-10-8)
• EPA Substance Registry System: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide(1236060-10-8)

Safety Data

• Hazardous Substances Data: 1236060-10-8(Hazardous Substances Data)

Upstream product

• 79607-24-2 6-methyl-4-carbonylquinoline-3-carboxylic acid ethyl ester 
• 1182822-31-6 5-amino-2,4-di-tert-butylphenyl methyl carbonate 
• 51726-39-7 6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 96-76-4 2,4-di-tert-Butylphenol 
• 873055-54-0 carbonic acid 2,4-di-tert-butyl-phenyl ester methyl ester 
• 873055-55-1 carbonic acid 2,4-di(tert-butyl)-5-nitrophenyl ester methyl ester 
• 19056-84-9 diethyl 2-[(p-tolylamino)methylidene]malonate 
• 106-49-0 p-toluidine 

Relevant articles and documents

Synthesis and biological evaluation of 4-oxoquinoline-3-carboxamides derivatives as potent anti-fibrosis agents

Thirty-one 4-oxoquinoline-3-carboxamides derivatives were synthesized and evaluated for their anti-fibrotic activities by the inhibition of TGF-β1-induced total collagen accumulation and anti-inflammatory activities by the inhibition of LPS-stimulated TNF-α production. Among them, three compounds (10a, 10l and 11g) exhibited potent inhibitory effects on both TGF-β1-induced total collagen accumulation and LPS-stimulated TNF-α production. Furthermore, oral administrations of 10l at a dose of 20 mg/kg/day for 4 weeks effectively alleviated lung inflammation and injury, and decreased lung collagen accumulation in bleomycin-induced pulmonary fibrosis model. Histopathological evaluation of lung tissue confirmed 10l as a potential, orally active agent for the treatment of pulmonary fibrosis.